XML 21 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Changes in Equity (unaudited) - USD ($)
$ in Millions
Total
Total Baxter stockholders' equity
Common stock
Common stock in treasury
Additional contributed capital
Retained earnings
Accumulated other comprehensive loss
Noncontrolling interests
Balance, beginning of period (in shares) at Dec. 31, 2023     683,000,000          
Balance, beginning of period (in usd) at Dec. 31, 2023 $ 8,468 $ 8,402 $ 683 $ (11,230) $ 6,389 $ 16,114 $ (3,554) $ 66
Balance, treasury, beginning period (in shares) at Dec. 31, 2023       176,000,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss 39 37       37   2
Other comprehensive income (loss) (172) (168)         (168) (4)
Stock issued under employee benefit plans and other (in shares)       (2,000,000)        
Stock issued under employee benefit plans and other 50 50   $ 100 (50)      
Dividends declared on common stock (148) (148)       (148)    
Change in noncontrolling interests (2)             (2)
Balance, end of period (in shares) at Mar. 31, 2024     683,000,000          
Balance, end of period (in usd) at Mar. 31, 2024 8,235 8,173 $ 683 $ (11,130) 6,339 16,003 (3,722) 62
Balance, treasury, ending period (in shares) at Mar. 31, 2024       174,000,000        
Balance, beginning of period (in shares) at Dec. 31, 2024     683,000,000          
Balance, beginning of period (in usd) at Dec. 31, 2024 $ 7,024 6,964 $ 683 $ (11,059) 6,421 14,929 (4,010) 60
Balance, treasury, beginning period (in shares) at Dec. 31, 2024 172,567,636     173,000,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss $ 126 126       126   0
Other comprehensive income (loss) (47) (47)         (47)  
Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation 115 115         115  
Stock issued under employee benefit plans and other (in shares)       (3,000,000)        
Stock issued under employee benefit plans and other 10 10   $ 122 (112)      
Dividends declared on common stock (87) (87)       (87)    
Disposition of noncontrolling interest associated with the Kidney Care separation (87)             (87)
Balance, end of period (in shares) at Mar. 31, 2025     683,000,000          
Balance, end of period (in usd) at Mar. 31, 2025 $ 7,054 $ 7,081 $ 683 $ (10,937) $ 6,309 $ 14,968 $ (3,942) $ (27)
Balance, treasury, ending period (in shares) at Mar. 31, 2025 170,414,885     170,000,000